Charles River Laboratories International Inc (CRL) concluded trading on Wednesday at a closing price of $187.91, with 0.49 million shares of worth about $92.67 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -7.30% during that period and on January 08, 2025 the price saw a loss of about -0.97%. Currently the company’s common shares owned by public are about 51.13M shares, out of which, 50.59M shares are available for trading.
Stock saw a price change of 1.79% in past 5 days and over the past one month there was a price change of -2.03%. Year-to-date (YTD), CRL shares are showing a performance of 1.79% which decreased to -17.19% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $176.48 but also hit the highest price of $275.00 during that period. The average intraday trading volume for Charles River Laboratories International Inc shares is 666.18K. The stock is currently trading 0.11% above its 20-day simple moving average (SMA20), while that difference is down -2.52% for SMA50 and it goes to -10.33% lower than SMA200.
Charles River Laboratories International Inc (NYSE: CRL) currently have 51.13M outstanding shares and institutions hold larger chunk of about 103.08% of that.
The stock has a current market capitalization of $9.61B and its 3Y-monthly beta is at 1.38. PE ratio of stock for trailing 12 months is 23.20, while it has posted earnings per share of $8.10 in the same period. Its PEG reads 8.08 and has Quick Ratio of 1.14 while making debt-to-equity ratio of 0.73. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CRL, volatility over the week remained 3.21% while standing at 2.99% over the month.
Analysts are in expectations that Charles River Laboratories International Inc (CRL) stock would likely to be making an EPS of 2.55 in the current quarter, while forecast for next quarter EPS is 2.34 and it is 10.34 for next year. For the current quarter EPS, analysts have given the company a lowest target 2.45 which is 2.65 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of 2.46 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -4.40% while it is estimated to increase by 0.79% in next year. EPS is likely to shrink at an annualized rate of 2.87% for next 5-years, compared to annual growth of 14.84% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by CLSA on November 18, 2024 offering an Underperform rating for the stock and assigned a target price of $164 to it. Coverage by CLSA stated Charles River Laboratories International Inc (CRL) stock as a Hold in their note to investors on November 07, 2024, suggesting a price target of $205 for the stock. Stock get an In-line rating from Evercore ISI on October 07, 2024.
